Why Sarepta Therapeutics Stock Is Rising Today

Shares of mid-cap biotech Sarepta Therapeutics (NASDAQ: SRPT) marched almost 11% higher Wednesday morning on elevated volume. The stock's rally was catalyzed by news of encouraging results from an early-stage muscle biopsy study for its experimental Duchenne muscular dystrophy (DMD) therapy, known as golodirsen. Duchenne is a genetic disorder causes muscle wasting; it primarily afflicts young boys, and is the result of a mutation on the X chromosome.

Golodirsen targets patients with deletions of the DMD gene amenable to skipping exon 53. If approved, it would complement the company's first DMD commercial product, Exondys 51. As of 10:30 a.m. EDT Wednesday, Sarepta's shares were up by 10.5%. 

Image Source: Getty Images.

Continue reading

Source: Fool.com